Clinical Trial News Archive - October 2024
October 1, 2024
- Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment
- Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH
- Zilganersen Granted U.S. FDA Fast Track Designation for People Living with Alexander Disease
October 2, 2024
- Eirion Therapeutics Announces Results of First-in-Human Clinical Trial Evaluating Ready-to-Use Liquid Injectable Neuromodulator AI-09 for the Treatment of Wrinkles
- Gilead Signs Royalty-Free Voluntary Licensing Agreements with Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
- ERLEADA demonstrates statistically significant and clinically meaningful improvement in overall survival compared to enzalutamide in patients with metastatic castration-sensitive prostate cancer
October 3, 2024
October 7, 2024
- First Healthy Volunteer Dosed with HT-4253, a Novel Oral LRRK2 Inhibitor Targeting Neuroinflammation in Alzheimer's Disease
- Ultragenyx Receives Breakthrough Therapy Designation for Setrusumab (UX143) in Osteogenesis Imperfecta
- TCI Unveils Promising GLP-1 Formula Clinical Trial Results for Advanced Weight Management
October 8, 2024
- PTC Therapeutics Announces Positive Results from Long-Term Treatment Studies and Updates on Regulatory Progress for Vatiquinone Friedreich Ataxia Program
- First Patient Dosed in Clinical Study of PT886 in Combination with Keytruda
- First Patients Dosed in Phase 1a/b Clinical Trial of RGT-61159, an Oral Small Molecule Targeting MYB, in Adenoid Cystic Carcinoma and Colorectal Cancer
- Boehringer Receives U.S. FDA Breakthrough Therapy Designation and Initiates Two Phase III trials in MASH for Survodutide
October 9, 2024
- FDA Grants Fast Track Designation For Biomarker-Guided DB104 (liafensine) in Patients with Treatment-Resistant Depression (TRD)
- Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
October 10, 2024
- Positive Top-line Results from Phase 3 Study of Effexor in Japanese Adults with Generalized Anxiety Disorder
- Volixibat Granted Breakthrough Therapy Designation for Cholestatic Pruritus in Primary Biliary Cholangitis
October 13, 2024
October 14, 2024
October 15, 2024
- Nipocalimab Demonstrates Sustained Disease Control in Adolescents Living with Generalized Myasthenia Gravis in Phase 2/3 study
- NIH and FDA Leaders Call for Innovation in Development of Smoking Cessation Treatments
October 16, 2024
- Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial
- Glaukos Announces Positive Topline Outcomes in Phase 3 Confirmatory Trial for Epioxa, Achieving Primary Efficacy Endpoint and Demonstrating Favorable Tolerability and Safety
October 17, 2024
- Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants
- Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome
October 18, 2024
October 19, 2024
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48
- Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom’s Macroglobulinemia
October 20, 2024
October 22, 2024
- Darling Ingredients Announces Publication of Peer-Reviewed Collagen Peptides Study and its Impact on Post-Meal Blood Glucose Spikes
- Alto Neuroscience Reports Topline Results from a Phase 2b Trial Evaluating ALTO-100 as a Treatment for Major Depressive Disorder
- Sangamo Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in Fabry Disease With BLA Submission Expected in 2025
- First participants enrolled in first-in-human Phase I clinical trial with nociceptin (NOP) receptor agonist
October 23, 2024
October 24, 2024
October 25, 2024
October 26, 2024
October 28, 2024
October 29, 2024
October 30, 2024
October 31, 2024
Clinical trial results archive
- 2025
- January, February, March, April, May
- 2024
- January, February, March, April, May, June, July, August, September, October, November, December
- 2023
- January, February, March, April, May, June, July, August, September, October, November, December
- 2022
- January, February, March, April, May, June, July, August, September, October, November, December
- 2021
- January, February, March, April, May, June, July, August, September, October, November, December
- 2020
- January, February, March, April, May, June, July, August, September, October, November, December
- 2019
- January, February, March, April, May, June, July, August, September, October, November, December
- 2018
- January, February, March, April, May, June, July, August, September, October, November, December
- 2017
- May, June, July, August, September, October, November, December
- 2016
- October
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.